Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake

Xenobiotica

Volumn 37, Issue 10-11, 2007, Pages 1110-1134

  Baker, M ^a,b,d   Parton, T ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UCB   (United Kingdom)

^c Research DMPK   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Hepatic clearance; Kinetics; Modelling; Plasma protein binding

Indexed keywords

COUMARIN; ETACRYNIC ACID; PHENYTOIN;

CELL METABOLISM; DRUG UPTAKE; HUMAN; LIVER; LIVER CLEARANCE; MODEL; NONHUMAN; PLASMA PROTEIN BINDING; REVIEW; SIMULATION;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD PROTEINS; HEPATOCYTES; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PROTEIN BINDING; RATS; XENOBIOTICS;

BOVINAE;

EID: 35648935952     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701658296     Document Type: Review

References (76)

1. Abu-Zahra TN, Pang KS. 2000. Effect of zonal transport and metabolism on hepatic removal: Enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metabolism and Disposition 28:807-813.
2. Akaike A. 1978. Posterior probabilities for choosing a regression model. Annals of the Institute of Mathematics and Statistics 30:A9-A14.
3. Andersson TB, Bredberg E, Ericsson H, Sjoberg H. 2004. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metabolism and Disposition 32:715-721.
4. Andersson TB, Sjoberg H, Hoffmann KJ, Boobis AR, Watts P, Edwards RJ, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, et al. 2001. An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metabolism and Disposition 29:712-720.
5. Annaert PP, Turncliff RZ, Booth CL, Thakker DR, Brouwer KL. 2001. P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metabolism and Disposition 29:1277-1283.
6. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. 2002. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metabolism and Disposition 30:1497-1503.
7. Austin RP, Barton P, Mohmed S, Riley RJ. 2005. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metabolism and Disposition 33:419-425.
8. Baba T, Touchi A, Ito K, Yamaguchi Y, Yamazoe Y, Ohno Y, Sugiyama Y. 2002. Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. Drug Metabolism and Pharmacokinetics 17:522-531.
9. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. 2007. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Current Drug Metabolism 8:33-45.
10. Berezhkovskiy LM. 2004. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. Journal of Pharmaceutical Science 93:364-374.
11. Bermejo M, Avdeef A, Ruiz A, Nalda R, Ruell JA, Tsinman O, Gonzalez I, Fernandez C, Sanchez G, Garrigues TM, et al. 2004. PAMPA - a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. European Journal of Pharmaceutical Science 21:429-441.
12. Bertucci C, Cimitan S. 2003. Rapid screening of small ligand affinity to human serum albumin by an optical biosensor. Journal of Pharmacology and Biomedicine Analysis 32:707-714.
13. Cai Z-S, Burczynski FJ, Luxon BA, Forker EL. 1992. On the design and interpretation of experiments to elucidate albumin-dependent hepatic uptake. American Journal of Physiology - Gastrointestinal and Liver Physiology 261:61127-61137.
14. Chandra P, Brouwer KL. 2004. The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research 21:719-735.
15. Chaturvedi PR, Decker CJ, Odinecs A. 2001. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Current Opinions in Chemistry and Biology 5:452-463.
16. Clarke SE, Jeffrey P. 2001. Utility of metabolic stability screening: Comparison of in vitro and in vivo clearance. Xenobiotica 31:591-598.
17. Day YS, Baird CL, Rich RL, Myszka DG. 2002. Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods. Protein Science 11:1017-1025.
18. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ. 2007. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metabolism and Disposition 35:649-659.
19. Forker EL, Luxon BA. 1981. Albumin helps mediate removal of taurocholate by rat liver. Journal of Clinical Investigation 67:1517-1522.
20. Foy BD, Toxopeus C, Frazier JM. 1999. Kinetic modeling of slow dissociation of bromosulphophthalein from albumin in perfused rat liver: Toxicological implications. Toxicology Science 50:20-29.
21. Frostell-Karlsson A, Remaeus A, Roos H, Andersson K, Borg P, Hamalainen M, Karlsson R. 2000. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. Journal of Medial Chemistry 43:1986-1992.
22. Gray MR, Tam YK. 1987. The series-compartment model for hepatic elimination. Drug Metabolism and Disposition 15:27-31.
23. Hagenbuch B, Scharschmidt BF, Meier PJ. 1996. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochemistry Journal 316:901-904.
24. Hallifax D, Houston JB. 2006. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metabolism and Disposition 34:1829-1836.
25. Hassen AM, Lam D, Chiba M, Tan E, Geng W, Pang KS. 1996. Uptake of sulfate conjugates by isolated rat hepatocytes. Drug Metabolism and Disposition 24:792-798.
26. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. 2007. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metabolism Reviews 39:159-234.
27. Hill WG, Southern NM, MacIver B, Potter E, Apodaca G, Smith CP, Zeidel ML. 2005. Isolation and characterization of the Xenopus oocyte plasma membrane: A new method for studying activity of water and solute transporters. American Journal of Physiology and Renal Physiology 289:F217-F224.
28. Horie T, Mizuma T, Kasai S, Awazu S. 1988. Conformational change in plasma albumin due to interaction with isolated rat hepatocyte. American Journal of Physiology 254:G465-G470.
29. Ito K, Houston JB. 2005. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmaceutical Research 22:103-112.
30. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. 1998. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annual Review of Pharmacology and Toxicology 38:461-499.
31. Ito K, Suzuki H, Horie T, Sugiyama Y. 2005. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharmaceutical Research 22:1559-1577.
32. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. 1996. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharmaceutics and Drug Disposition 17:273-310.
33. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. 1999. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. Journal of Pharmacology and Experimental Therapeutics 288:627-634.
34. Lave T, Coassolo P, Reigner B. 1999. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clinical Pharmacokinetics 36:211-231.
35. Letschert K, Faulstich H, Keller D, Keppler D. 2006. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicology Science 91:140-149.
36. Li AP, Sakai H, Lu C, Fackett A, Lin JH. 2000. Protein binding and metabolism: Effects of human serum albumin on coumarin metabolism in human hepatocytes. Poster presented at the AAPS Annual Meeting, 2000.
37. Liu L, Pang KS. 2005. The roles of transporters and enzymes in hepatic drug processing. Drug Metabolism and Disposition 33:1-9.
38. Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. 1999. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metabolism and Disposition 27:637-644.
39. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. 2006. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: Evaluation of free fraction and uptake in hepatocytes. Drug Metabolism and Disposition 34:1600-1605.
40. Ludden LK, Ludden TM, Collins JM, Pentikis HS, Strong JM. 1997. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: Implications for clinical correlation. Journal of Pharmacology and Experimental Therapy 282:391-396.
41. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. 2003. Impact of drug transporter studies on drug discovery and development [Review]. Pharmacological Reviews 55:425-461.
42. Nijssen HM, Pijning T, Meijer DK, Groothuis GM. 1992. Influence of albumin on the net sinusoidal efflux of the organic anion dibromosulfophthalein from rat liver. Hepatology 15:302-309.
43. Nijssen HM, Pijning T, Proost JH, Meijer DK, Groothuis GM. 1994. The sinusoidal efflux of dibromosulfophthalein from rat liver is stimulated by albumin, ligandin and fatty acid binding protein but not by other dibromosulfophthalein binding proteins. Journal of Hepatology 12:29-36.
44. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I. 2004. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: Implications for understanding troglitazone hepatotoxicity. Drug Metabolism and Disposition 32:291-294.
45. Obach RS. 1997. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metabolism and Disposition 25:1359-1369.
46. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27:1350-1359.
47. Qian D, Brosnan JT. 1996. Administration of Escherichia coli endotoxin to rat increases liver mass and hepatocyte volume in vivo. Biochemistry Journal 313(Pt 2):479-486.
48. Rane A, Wilkinson GR, Shand DG. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapy 200:420-424.
49. Reasor MJ, Hastings KL, Ulrich RG. 2006. Drug-induced phospholipidosis: Issues and future directions. Expert Opinions in Drug Safety 5:567-583.
50. Rich RL, Day YS, Morton TA, Myszka DG. 2001. High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE. Annals in Biochemistry 296:197-207.
51. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metabolism and Disposition 33:1304-1311.
52. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. 2002. Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics 41:751-790.
53. Schwarz G. 1978. Estimating the dimension of a model. Annals of Statistics 6:461-464.
54. Shibata Y, Takahashi H, Chiba M, Ishii Y. 2002. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metabolism and Disposition 30:892-896.
55. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. Journal of Pharmacology and Experimental Therapy 304:610-616.
56. Siebert GA, Hung DY, Chang P, Roberts MS. 2004. Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. Journal of Pharmacology and Experimental Therapy 308:228-235.
57. Soars MG, Burchell B, Riley RJ. 2002. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. Journal of Pharmacology and Experimental Therapy 301:382-390.
58. Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. 2007a. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metabolism and Disposition 35:859-8605.
59. Soars MG, McGinnity DF, Grime K, Riley RJ. 2007b. The pivotal role of hepatocytes in drug discovery. Chemico-Biology Interactions 20(168):2-15.
60. Sun H, Huang Y, Frassetto L, Benet LZ. 2004. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metabolism and Disposition 32:1239-1246.
61. Tan E, Tirona RG, Pang KS. 1999. Lack of zonal uptake of estrone sulfate in enriched periportal and perivenous isolated rat hepatocytes. Drug Metabolism and Disposition 27:336-341.
62. Tirona RG, Pang KS. 1999. Bimolecular glutathione conjugation kinetics of ethacrynic acid in rat liver: In vitro and perfusion studies. Journal of Pharmacology and Experimental Therapeutics 290:1230-1241.
63. Tirona RG, Tan E, Meier G, Pang KS. 1999. Uptake and glutathione conjugation of ethacrynic acid and efflux of the glutathione adduct by periportal and perivenous rat hepatocytes. Journal of Pharmacology and Experimental Therapeutics 291:1210-1219.
64. Toutain PL, Bousquet-Melou A. 2002. Free drug fraction vs free drug concentration: A matter of frequent confusion. Journal of Veterinary and Pharmacological Therapy 25:460-463.
65. Van de Water FM, Masereeuw R, Russel FG. 2005. Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metabolism Reviews 37:443-471.
66. Van den Bongard HJ, Kemper EM, Van Tellingen O, Rosing H, Mathot RA, Schellens JH, Beijnen JH. 2004. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Analytical Biochemistry 324:11-15.
67. Van Dyke RW, Faber ED, Meijer DK. 1992. Sequestration of organic cations by acidified hepatic endocytic vesicles and implications for biliary excretion. Journal of Pharmacology and Experimental Therapy 261:1-11.
68. Weisiger RA. 1985. Dissociation from albumin: A potentially rate-limiting step in the clearance of substances by the liver. Proceedings of the National Academy of Sciences, USA 82:1563-1567.
69. Weisiger RA, Pond S, Bass L. 1991. Hepatic uptake of protein-bound ligands: Extended sinusoidal perfusion model. American Journal of Physiology 261:G872-G884.
70. Weisiger RA, Pond SM, Bass L. 1989. Albumin enhances unidirectional fluxes of fatty acid across a lipid-water interface: Theory and experiments. American Journal of Physiology 257:G904-G916.
71. Wright JD, Boudinot FD, Ujhelyi MR. 1996. Measurement and analysis of unbound drug concentrations. Clinical Pharmacokinetics 30:445-462.
72. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. 1996a. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharmaceutical Research 13:1559-1564.
73. Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y. 1993. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. American Journal of Physiology 264:G36-G44.
74. Yamazaki M, Suzuki H, Sugiyama Y, Iga T, Hanano M. 1992. Uptake of organic anions by isolated rat hepatocytes. A classification in terms of ATP-dependency. Journal of Hepatology 14:41-47.
75. Yamazaki M, Suzuki H, Sugiyama Y. 1996b. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. [Review]. Pharmaceutical Research 13:497-513.
76. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. 2007. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. European Journal of Pharmaceutical Science 31:232-234.